Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.54 |
| ▸ | ITK | Q08881 | 6/20 | 0.54 |
| ▸ | BTK | Q06187 | 4/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | BLK | P51451 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7246188 | 0.83 | SCN9A (0.58) | SCN9A | |
| SCHEMBL7246192 | 0.83 | SCN9A (0.47) | BTKSCN9AJAK3 | |
| SCHEMBL6483198 | 0.80 | EGFR (0.49) | EGFRITKBTKSRCBLK | |
| SCHEMBL6483184 | 0.79 | EGFR (0.52) | EGFRITKBTKSRCBLK | |
| SCHEMBL6483156 | 0.77 | EGFR (0.64) | EGFRITKBTKSRCBLK | |
| SCHEMBL7120364 | 0.76 | EGFR (0.71) | EGFRBTKSRCBLKJAK3 | |
| SCHEMBL7123114 | 0.76 | EGFR (0.62) | EGFRSRC | |
| SCHEMBL30423172 | 0.74 | EGFR (0.61) | EGFRITKBTKSRCBLK | |
| SCHEMBL28400866 | 0.74 | EGFR (0.61) | EGFRITKBTKSRCBLK | |
| SCHEMBL6482765 | 0.71 | JAK3 (0.57) | EGFRITKBTKSRCBLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | claimed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | claimed |
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1390354-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | Amgen Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2002083653-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | EGFR 228/4885ITK 755/4885BTK 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.